THURSDAY, SEPTEMBER 29, 2016

Sinovac receives award to supply hepatitis A vaccine in Jiangsu province

Sinovac Biotech, Ltd., announced on Thursday that it was selected by the Jiangsu Centers for Disease Control and Prevention to supply its inactivated hepatitis A vaccine to the Jiangsu province's pediatric population.

Sinovac, a China-based vaccine manufacturer, will supply up to 900,000 doses of its vaccine, Healive, under the Jiangsu CDC's Expanded Program of Immunization beginning next year. Sinovac was one of two suppliers selected to supply a hepatitis A vaccine to the province. The total volume of the tender is up to 1.8 million doses.

"We are pleased to be selected once again by the Jiangsu CDC as one of the two suppliers of inactivated hepatitis A vaccine pursuant to the tender for the 2014 EPI," Weidong Yin, the chairman, president and CEO of Sinovac, said. "We are advancing our strategy to collaborate with the government agencies to provide top-quality vaccines to prevent and control diseases in China and beyond."

Healive is the first inactivated hepatitis A vaccine that was developed, produced and marketed by a manufacturer in China. Sinovac launched Healive in 2002 in China. The vaccine is currently available in pediatric and adult dosage forms.

The Chinese government began including hepatitis A vaccine in its national immunization program in February 2008.